Liverpool HEP Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Potential Interaction

Sofosbuvir/Velpatasvir

Doravirine/Lamivudine/Tenofovir-DF

Summary:

Coadministration has not been studied. Doravirine and lamivudine are not expected to inhibit or induce any relevant metabolic enzymes or transporters of sofosbuvir/velpatasvir. However, sofosbuvir/velpatasvir increased tenofovir AUC by ~30-80% when administered with various regimens containing tenofovir-DF. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed. Monitor for tenofovir-associated adverse reactions.

Description:

Epclusa has been shown to increase tenofovir exposure (P-gp inhibition). The increase in tenofovir exposure (AUC and Cmax) was around 40-80% during co-treatment with Epclusa and tenofovir disoproxil fumarate/emtricitabine as part of various HIV regimens. Monitor for tenofovir-associated adverse reactions in patients receiving Epclusa concomitantly with a regimen containing tenofovir DF. Refer to the prescribing information of the tenofovir DF-containing product for recommendations on renal monitoring.

Epclusa Summary of Product Characteristics, Gilead Sciences Ltd., March 2021.

Coadministration increases tenofovir concentrations. Monitor for tenofovir-associated adverse reactions in patients receiving Sofosbuvir/velpatasvir concomitantly with a regimen containing tenofovir DF. Refer to the prescribing information of the tenofovir DF-containing product for recommendations on renal monitoring.

Coadministration of tenofovir (300 mg once daily, administered as emtricitabine/rilpivirine/tenofovir-DF) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 24 subjects. Tenofovir Cmax, AUC and Cmin increased by 44%, 40% and 84%, respectively. Coadministration also results in comparable increases in tenofovir exposures when TDF is administered as EFV/FTC/TDF, elvitegravir/cobicistat/FTC/TDF), FTC/TDF + atazanavir/ritonavir, FTC/TDF + darunavir/ritonavir, or RAL + FTC/TDF.

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

View all available interactions with Sofosbuvir/Velpatasvir by clicking here.